The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
 
Sukhmani Kaur Padda
Honoraria - CME Solutions; Curio Science; Janssen; Jazz Pharmaceuticals; MECC Global Meetings; Medical Oncology Association of Southern California; Medical Oncology Association of Southern California; Nanobiotix; OncLive/MJH Life Sciences; Physicans' Education Resource
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Blueprint Medicines; G1 Therapeutics; Genentech; Genzyme; Janssen Oncology; Janssen Oncology; Jazz Pharmaceuticals; Mirati Therapeutics; Mirati Therapeutics; RayzeBio; Regeneron
Research Funding - BioAtla (Inst); Takeda (Inst)
Other Relationship - OncLive/MJH Life Sciences
 
Mary Weber Redman
No Relationships to Disclose
 
David E Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - BeiGene; Catalyst Pharmaceuticals; Daichi Sankyo; Janssen Oncology; Mirati Therapeutics; Regeneron; Sanofi
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Karyopharm Therapeutics (Inst); Novocure (Inst)
Patents, Royalties, Other Intellectual Property - Co-founder, Chief Scientific Officer, OncoSeer Diagnostics, LLC; Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.; UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 4153 - US Patent Application 63/386,387 IMMUNOTHERAPY TOXICITY – CELL PHENOTYPES; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb
 
Tom Stinchcombe
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Eisai/H3 Biomedicine; G1 Therapeutics; Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Mirati Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
 
Saiama Naheed Waqar
Research Funding - Abbvie (Inst); ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cullinan Pearl (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Ignyta (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Millennium (Inst); Newlink Genetics (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Roche (Inst); Verastem (Inst); Vertex (Inst); Xcovery (Inst)
 
Ticiana Leal
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Daiichi-Sankyo; Eisai; EMD Serono; EMD Serono; Genentech; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Merck; Mirati Therapeutics; Novocure; Novocure; Novocure; Regeneron; Roche; Takeda; Takeda
Research Funding - Pfizer (Inst)
 
Katherine Minichiello
No Relationships to Disclose
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech; GlaxoSmithKline; Janssen Oncology; Lilly; Merck KGaA; Mirati Therapeutics; Seagen; Takeda
Research Funding - Blueprint Medicines; Calithera Biosciences (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)
 
Roy S. Herbst
Leadership - American Association for Cancer Research; IASLC; Immunocore; Junshi Pharmaceuticals; Society for Immunotherapy of Cancer; SWOG
Stock and Other Ownership Interests - Bolt Biotherapeutics; Checkpoint Therapeutics; Immunocore; Normunity
Consulting or Advisory Role - Abbvie; AstraZeneca; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics; Checkpoint Therapeutics; Cybrexa Therapeutics; DynamiCure Biotechnology; eFFECTOR Therapeutics; EMD Serono; Genentech/Roche; Gilead/Forty Seven; HiberCell; I-Mab; Immune-Onc Therapeutics; Janssen; Johnson and Johnson; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; NextCure; NextCure; Normunity; Novartis; Ocean Biomedical; OncoCyte; Oncternal Therapeutics; Pfizer; Refactor Health; Regeneron; Revelar; Ribon Therapeutics; Sanofi; Seagen; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
Travel, Accommodations, Expenses - American Cancer Society; IASLC; SWOG
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Pfizer; Regeneron
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Beigene; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; Da Volterra; EMD Serono; Genentech; Genmab; Guardant Health; HUYA Bioscience International; ITeos Therapeutics; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; natera; Novartis; oncocyte; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Regeneron
Other Relationship - Incyte; Novartis; SpringWorks Therapeutics; Takeda; University of Pennsylvania
 
Julie R. Brahmer
Honoraria - Janssen
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech; GlaxoSmithKline; Incyte; Merck; Regeneron; Sanofi
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); RAPT Therapeutics (Inst); Spectrum Pharmaceuticals (Inst)
Other Relationship - Bristol-Myers Squibb; Merck; Regeneron
 
Jhanelle Elaine Gray
Honoraria - Jazz Pharmaceuticals; Merck; OncoCyte
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Bristol Myers Squibb; EMD Serono; Janssen Scientific Affairs; Jazz Pharmaceuticals; Lilly; Loxo; Merck Sharp & Dohme; National Comprehensive Cancer Network; Novartis; Sanofi
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); ECOG-ACRIN (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); SWOG (Inst)
Travel, Accommodations, Expenses - Novartis; OncoCyte
 
Karen Kelly
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Daiichi Sanko; Debiopharm Group; Eisai; EMD Serono; Genentech; Genmab; Janssen; Lilly; Novartis; Regeneron; Sanofi; Takeda; Targeted Oncology
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Meyers Squibb (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
 
Suresh S. Ramalingam
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca
Other Relationship - American Cancer Society
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; HMP Education; Medical Educator Consortium; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Calithera Biosciences; D2G Oncology; Exelixis; Genentech/Roche; Gilead Sciences; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Mirati Therapeutics; Natera; Novartis; Novocure; Regeneron; Sanofi/Regeneron; Summit Therapeutics; Surface Oncology; Takeda; Turning Point Therapeutics
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties